7210 Wareham Drive, Tampa, FL 33647
Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting […]
Weight Loss Pills Are On The Horizon Read More »
Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium
Pfizer to Buy Weight-Loss Drug Developer Metsera Read More »
Sept. 12, 2025 According to an article by Food Navigator, the ketogenic diet, popular since the 1990s, is in decline, faced by consumer fatigue over restrictive requirements and strong competition from the GLP-1 medications. Analysts at Tastewise say that social mentions of keto dropped 18% by mid-year 2025 versus the prior year. Keto’s complex and
Keto Diet Is On The Decline Read More »
Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which
FDA Tightens Oversight of GLP-1 Ingredients Imports Read More »
Sept. 8, 2025 WW today announced the launch of Weight Watchers for Menopause, a program that is designed to support women through every stage of the menopause journey, from perimenopause to post-menopause. To launch the program, WeightWatchers is partnering with Grammy and Emmy Award-winning and Oscar-nominated actress, producer, entrepreneur, and health advocate Queen Latifah as
Queen Latifah To Pitch New Weight Watchers Menopause Program Read More »
Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside
Weight Watchers Hires New International V.P. Read More »
August 11, 2025 The company emerged from its financial reorganization process on June 24, 2025. According to Tara Comonte, CEO of Weight Watchers: “This marks the beginning of an exciting new chapter for the Company, one that’s grounded in stronger financial footing and a clear sense of opportunity. With greater flexibility to invest, we’re accelerating
Weight Watchers Reports Q2 2025 Results Read More »
August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and
Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »
August 5, 2025 Noom is not giving up in the fight to provide GLP-1 drugs, despite pressure from Novo and Eli Lilly to stop selling compounded meds. It is now offering a “micro dose” plan. This program provides access to GLP-1 medication (if prescribed by a clinician), but at a lower, “microdose” level compared to
Noom To Offer GLP-1 Microdose Plan Read More »
August 4, 2025 “We are working diligently to transform our business as we look to help more people achieve optimal metabolic health,” said Dan Chard, CEO of Medifast. “We’re focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and
Medifast Reports Q2 Results – Slide Continues Read More »